CareDx Q3 2026 slides: 39% revenue growth, guidance raised $30M
CareDx (CDNA) reported Q3 2026 revenue of $139M, up 39% YoY, and raised full-year guidance to $520M-$530M. Testing services grew 65% YoY, with strong margins and profitability. Shares surged 15.07% in after-hours trading. The company highlighted clinical data and strategic initiatives.
How this was made
The 30-second read
Why it matters
The key tradable catalyst is the raised 2026 revenue and adjusted EBITDA guidance alongside reported Q3 growth, margin expansion, and integration milestones that can change forward estimates quickly.
Market read
Raised full-year guidance with specific revenue and adjusted EBITDA targets is likely to drive near-term estimate revisions and momentum in CDNA.
What to watch
The article cites Medicare reimbursement of $1,800 for NavDx and out-of-period collections; traders may discount sustainability of pricing and cash collections into future quarters.
Background
CareDx is expanding transplant molecular monitoring and integrating NavDx into its Epic Aura workflow, while building a specialty oncology platform via the Naveris acquisition.
Ticker impact
CareDx raised full-year 2026 revenue guidance to $520M-$530M and adjusted EBITDA to $90M-$100M after Q3 results, driving a sharp after-hours jump.
Likely upward bias as the market reprices 2026 growth and profitability expectations following the guidance raise.
The article reports the company’s own Q3 performance plus a specific, larger full-year guidance range and notes a same-day after-hours surge tied to the release.
Market effects
Supports sentiment for transplant and molecular diagnostics demand, especially around EMR workflow integration and higher-margin testing mix.
Limited, primarily affects US small/mid-cap biotech and diagnostics sentiment rather than broad regional flows.
Low, largely company-specific guidance and clinical workflow integration details.
Counterpoint
Guidance upside may be sensitive to reimbursement assumptions and integration execution (Epic Aura timing, NavDx adoption), which could moderate results if adoption lags.
Key entities
- companyCareDx
NASDAQ-listed molecular diagnostics company reporting Q3 2026 results and raising full-year 2026 guidance.
- productNavDx
Specialty oncology test whose integration into Epic Aura is expected by Jan. 1, 2027.
- productAlloSure
Transplant monitoring test referenced in patient portal adoption and clinical evidence.
- acquisitionNaveris
Specialty oncology platform acquired July 1, contributing to specialty oncology volume in Q3.
